Business
Agenus Corporate Update and Third Quarter 2021 Financial Report
Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types,
About this update from Agenus Inc.
[{"type":"text","content":"Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapyAgenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in colorectal and several gynecological cancersAgenus’ cell therapy affiliate, MiNK Therapeutics (NASDAQ: INKT), launched as a publicly traded company with >$40 million raised to accelerate clinical developmentAGEN1777, an Fc-enhanced TIGIT bispecific antibody, entered Phase 1 development, triggering a $20M milestone payment from Bristol Myers SquibbAfter successfully achieving clinical milestones and passing FDA inspections, Agenus withdrew its BLA for balstilimab based on FDA guidance; given the clinical benefit demonstrated by balstilimab, Agenus plans to launch an expanded access program in several countries LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2021. “With more than 100 patients treated with our Fc-enhanced CTLA-4 antibody, AGEN1181, we are very encouraged by the clinical responses achieved across tumor types. Of note, we are seeing responses in patients who have failed to respond to all other treatment, including PD-1 inhibitors,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “We will be presenting detailed trial results at the SITC conference this week. We have also successfully completed an initial public offering for MiNK Therapeutics, and have launched our adjuvant business, SaponiQx.” AGEN1181 (Fc-enhanced CTLA-4), as a monotherapy and in combination with balstilimab (anti PD-1), shows clinical benefit in 9 cold and treatment-resistant tumor types; data to be presented at SITC First presentation of clinical data from 100+ patients who represent a heavily pre-treated population, and were administered AGEN1181 as a monotherapy or in combination with balstilimabEvidence of AGEN1181 monotherapy activity with multiple confirmed responses: microsatellite stable (MSS) - endometrial cancer (CR), melanoma (PR), cervical cancer ...